Abstract |
As a result of thermal instability, some live attenuated viral (LAV) vaccines lose substantial potency from the time of manufacture to the point of administration. Developing regions lacking extensive, reliable refrigeration ("cold-chain") infrastructure are particularly vulnerable to vaccine failure, which in turn increases the burden of disease. Development of a robust, infectivity-based high throughput screening process for identifying thermostable vaccine formulations offers significant promise for vaccine development across a wide variety of LAV products. Here we describe a system that incorporates thermal stability screening into formulation design using heat labile measles virus as a prototype. The screening of >11,000 unique formulations resulted in the identification of liquid formulations with marked improvement over those used in commercial monovalent measles vaccines, with <1.0 log loss of activity after incubation for 8h at 40°C. The approach was shown to be transferable to a second unrelated virus, and therefore offers significant promise towards the optimization of formulation for LAV vaccine products.
|
Authors | Lisa D Schlehuber, Iain J McFadyen, Yu Shu, James Carignan, W Paul Duprex, William R Forsyth, Jason H Ho, Christine M Kitsos, George Y Lee, Douglas A Levinson, Sarah C Lucier, Christopher B Moore, Niem T Nguyen, Josephine Ramos, B André Weinstock, Junhong Zhang, Julie A Monagle, Colin R Gardner, Juan C Alvarez |
Journal | Vaccine
(Vaccine)
Vol. 29
Issue 31
Pg. 5031-9
(Jul 12 2011)
ISSN: 1873-2518 [Electronic] Netherlands |
PMID | 21616113
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2011 Elsevier Ltd. All rights reserved. |
Chemical References |
- Excipients
- Measles Vaccine
|
Topics |
- Chemistry, Pharmaceutical
(methods)
- Drug Stability
- Excipients
(chemistry)
- High-Throughput Screening Assays
(methods)
- Humans
- Measles Vaccine
(chemistry)
- Measles virus
(drug effects, pathogenicity, radiation effects)
- Temperature
|